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Introduction 
Glucuronidation is a phase II metabolic reaction catalyzed by UDP-glucuronosyltransferase 
(UGT) that transforms endogenous substances and xenobiotics into more hydrophilic compounds that 
are subsequently eliminated through excretion of urine and/or bile. Most lipophilic drugs are initially 
metabolized by cytochrome P450 (P450). Therefore, during the discovery stage of new chemical 
entities (NCEs), pharmaceutical companies focus more on preventing the metabolism of these drugs 
by P450. However, over the last decade, more hydrophilic compounds have been synthesized, and 
new concerns regarding UGT-catalyzed metabolism have been revealed because these processes are 
important for detoxification and prolongation of efficacy of some drugs. UGTs are widely expressed 
in various tissues including the liver, kidney, and gastrointestinal tract, implying that extrahepatic 
metabolism may exert a critical influence on the pharmacokinetics of glucuronidated drugs. It is well 
known that phenolic compounds including opioid analgesics such as morphine and flavonoids are 
extensively glucuronidated in the liver and small intestine (Ritter, 2007). In some cases, poor oral 
bioavailability (F) of the drugs is attributed to the susceptibilities to glucuronidation. Therefore, 
extrapolation of in vitro glucuronidation data to in vivo pharmacokinetic parameters is essential but 
difficult because of the complex nature of UGT enzymes (Lin and Wong, 2002). Several studies on in 
vitro-in vivo correlation (IVIVC) for UGT substrates have been published recently (Kilford et al., 
2009; Miners et al., 2010). It was reported that in vitro predictability depends on enzyme sources, 
experimental conditions, and the occurrence of atypical glucuronidation kinetics, and thus selection of 
an appropriate approach is a key point to predict pharmacokinetics successfully. In the chapter I, 
intestinal and hepatic glucuronidation of four compounds including raloxifene, which are mainly 
eliminated through glucuronidation, were examined by microsomal incubation and compared with in 
vivo clearances. The product of fraction absorbed and intestinal availability (Fa･Fg) and hepatic 
availability (Fh) of the four compounds were estimated in rats by monitoring the concentration in the 
portal and systemic blood after oral administration. Furthermore, to clarify the involvement of Ugt1As 
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in the glucuronidation of raloxifene, the pharmacokinetic profiles of raloxifene in Ugt1A-deficient 
rats (Gunn rats) were compared with those of their wild-type (Wistar) rats. 
Organic anions such as carboxylic drugs and phase II metabolites are actively transported by 
organic anion transporting polypeptides (Oatps), multidrug resistance-associated proteins (Mrps), and 
other transporters. Oatps and Mrps play a major role in sinusoidal uptake, canalicular excretion, and, 
to some extent, basolateral efflux in the liver. In the drug development process, it is important to know 
which transporters are involved in the disposition of organic anions in the liver, and ultimately at what 
level these compounds are systemically exposed. Although interspecies differences in hepatic uptake 
and biliary excretion of organic anions are common (Soars et al., 2007; Gardiner et al., 2011; Li et al., 
2008; Grime et al., 2013), no general rule explaining the differences in the disposition of organic 
anions between experimental animals and humans has been established. Therefore, extrapolation of 
pharmacokinetics from preclinical animals to humans is still a challenge for these compounds, 
particularly if carrier-mediated transport is involved. In the chapter I, a large difference in the 
systemic exposure of raloxifene glucuronides as major metabolites between Sprague–Dawley (SD) 
rats and Mrp2-deficient rats, Eisai hyperbilirubinemic rats (EHBRs), was observed: the blood 
concentration ratio of raloxifene glucuronides to the parent drug was greater in EHBRs (129) than that 
in SD rats (10). Thus, in the Chapter II, we focused particularly on the pharmacokinetic differences of 
three organic anions including raloxifene-6-glucuronide (R6G) between SD rats and EHBRs to 
determine whether they could be explained solely by a difference in its biliary excretion process. 
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I-i. Introduction 
Raloxifene is a selective estrogen receptor modulator used for the prevention and treatment 
of postmenopausal osteoporosis and for the prevention of breast cancer. Its bioavailability (F) in 
humans has been reported as only 2% (Eli Lilly clinical data, Indianapolis, IN; Mizuma, 2009). 
UGT1A8 and UGT1A10, isozymes that are absent in the human liver, are thought to glucuronidate 
raloxifene mainly in the intestine and lead to extremely low F (Kemp et al., 2002; Jeong et al., 2005). 
F of raloxifene in rats and dogs was originally reported as 39 and 17%, respectively (Lindstrom et al., 
1984), and have been recently reported as 4 and 0%, respectively (Deguchi et al., 2011). The Ugt 
isozymes responsible for the glucuronidation of raloxifene and its intestinal and hepatic availabilities 
(Fg and Fh, respectively) in preclinical animals have not been investigated adequately. It has been 
reported that raloxifene and its conjugates were excreted into the bile and gut lumen by 
P-glycoprotein and/or MRPs, and these efflux transports are considered to participate in the 
long-lasting enteric recycling of this drug (Jeong et al., 2004; Xu et al., 2009). At present, human 
UGT isoforms responsible for glucuronidating some drugs are being investigated in detail; however, 
much less is known about Ugts in animals, species differences in intestinal and hepatic 
glucuronidation, and subsequent excretion of glucuronides. 
In the present study, raloxifene and its glucuronides in the portal and systemic blood were 
monitored after oral administration in rats and dogs to estimate the contribution of intestinal and 
hepatic glucuronidation to the first-pass effect. This approach confirmed the species differences in Fa･
Fg and Fh of raloxifene. The in vitro intestinal and hepatic intrinsic clearance (CLint) values, which 
were corrected to CLint, u using microsomal binding in the incubation mixture, were determined using 
rat, dog, monkey, and human microsomes fortified with UDPGA or NADPH, and the IVIVCs were 
also examined. To clarify the involvement of Ugt1As in the glucuronidation of raloxifene and the role 
of Mrp2 in the excretion of its glucuronides, the pharmacokinetic profiles of raloxifene in Gunn rats 
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and EHBRs were compared with those of their wild-type (Wistar and SD) rats. Furthermore, the 
IVIVCs of several other compounds (biochanin A, mycophenolic acid, and gemfibrozil), which are 
mainly eliminated through glucuronidation in rats, were also investigated. The purpose of this study 
was to examine the usefulness of in vitro microsomal assays of intestinal and hepatic glucuronidation 
in improving the pharmacokinetic profiles of NCEs during drug discovery. 
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I-ii. Materials and Methods 
Reagents. Raloxifene, β-glucuronidase (type IX-A, from Escherichia coli), glucose 6-phosphate, and 
NADP were purchased from Sigma-Aldrich (St. Louis, MO). Mycophenolic acid, biochanin A, 
gemfibrozil, and EDTA were purchased from Wako Pure Chemicals (Osaka, Japan). 
Glucose-6-phosphate dehydrogenase and protease inhibitor cocktail tablets (Complete, EDTA-free) 
were purchased from Roche (Mannheim, Germany). The UGT reaction mix solution (250 mM 
Tris-HCl, 40 mM MgCl2, and 0.125 mg/ml alamethicin) was purchased from BD Gentest (Woburn, 
MA). Liver and intestinal microsomes from SD rats, beagle dogs, cynomolgus monkeys, and humans 
were obtained from XenoTech, LLC (Lenexa, KS). All chemicals were analytical grade or the highest 
quality available. 
Animals. All animal procedures were conducted under protocols approved by the Mitsubishi Tanabe 
Institutional Animal Care and Use Committee. Eight-week-old male Wistar rats, SD rats, Gunn rats, 
and EHBRs were obtained from Japan SLC (Shizuoka, Japan). Male SD rats (9–10 weeks old) with 
catheters implanted in the portal and jugular vein were obtained from Charles River Japan (Yokohama, 
Japan). Rats were kept in a temperature- and humidity-controlled environment and were allowed to 
acclimate for 1 week before use. Male beagle dogs (7–17 months old) were obtained from Kitayama 
Labs (Nagano, Japan). Male cynomolgus monkeys (42–61 months old) were obtained from 
Nafovanny (Dong Nai, Vietnam). These animals were housed in Mitsubishi Chemical Medience 
facilities where the temperature and humidity were controlled. 
Preparation of Microsomes. To compare the metabolic activities of different strains of rats, liver and 
intestinal microsomes from SD rats, EHBRs, Wistar rats, and Gunn rats were prepared (pooled, n = 3). 
Rat liver microsomes were prepared using standard techniques (von Moltke et al., 1993). In brief, 
pooled microsomes from three individuals were prepared by ultracentrifugation (11,900g for 20 min 
and 104,700g for 1 h twice). Microsomal pellets were resuspended in 0.1 M phosphate-buffered saline 
(PBS) (pH 7.4) containing 20% glycerol. The total protein concentration was determined using a BCA 
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Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA) using bovine serum albumin (BSA) as a 
standard. The prepared microsomes were stored at −80°C until use. Rat intestinal microsomes were 
prepared as described in a previous study by another group (Perloff et al., 2004). In brief, after 
exsanguination, 15-cm sections of the upper intestines from the duodenum to the jejunum were 
immediately isolated, and the intestinal segments were flushed and incubated in solution A (pH 7.3) 
containing 1.5 mM KCl, 96 mM NaCl, 27 mM sodium citrate, 9.6 mM PBS, and protease inhibitor 
(20 tablets/l) with bubbling oxygen for 15 min at 4°C. The intestinal segments were filled with 
solution B (pH 7.0) containing 1.5 mM KCl, 96 mM NaCl, 1.5 mM EDTA, 1 mM dithiothreitol, 0.1% 
BSA, 9.6 mM PBS, and protease inhibitor (20 tablets/l). After tapping the intestinal segments on an 
ice-cooled plate for 2 min to peel the epithelial cells off the intestinal wall, the suspension in the 
lumen was collected. The suspension was centrifuged at 800g for 10 min, and the resulting pellets 
were resuspended in solution C (pH 7.0) containing 5 mM histidine, 0.25 M sucrose, 0.5 mM EDTA, 
and protease inhibitor (20 tablets/l). The cell pellets were washed with solution C and homogenized 
and centrifuged at 15,000g for 10 min. The supernatant was collected, and 5 volumes of 52 mM CaCl2 
were added. The tubes containing microsomes were gently mixed, allowed to stand for 15 min, and 
centrifuged at 2000g for 10 min. The resulting microsomal pellets were suspended in solution D (pH 
7.4) containing 20% glycerol, 10 mM EDTA, and 0.1 M Tris-HCl buffer. The total protein 
concentration was determined by the BCA protein assay, and the microsomes were stored at −80°C 
until use. 
Microsomal Incubation. CLint was determined using the substrate depletion method (n = 3–5). 
Substrate solutions were prepared at a final concentration of 2 M in dimethyl sulfoxide and 
acetonitrile (0.01 and 0.99% final concentrations, respectively) except for gemfibrozil (10 M final 
concentration). The substrates were incubated in 96-well plates and placed on a heating block at 37°C. 
The suspensions containing microsomes (0.5 mg/ml protein except for biochanin A, 0.1 mg/ml 
protein) were either dispensed into the 50 mM Tris-HCl solution (pH 7.5) with 25 g/ml alamethicin 
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and 8 mM MgCl2 for UGT reactions or into the 72.5 mM PBS with 5 mM MgCl2 and 1 mM EDTA 
for P450 reactions as final concentrations. The suspensions were vortexed and allowed to stand for 10 
min in the heating block, and the metabolism assay was initiated by addition of 2 mM UDPGA or the 
NADPHgenerating system containing 1 mM NADP, 10 mM glucose 6-phosphate, and 2 units/ml 
glucose-6-phosphate dehydrogenase as final concentrations. All assays were incubated for a 
maximum of 60 min, and reactions were terminated with 4 volumes of acetonitrile containing 0.1% 
formic acid and verapamil as the internal standard (IS). The samples were then centrifuged, and the 
supernatant was filtered and transferred to the other 96-well plates for analysis using a liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) system as described below.  
Microsomal Binding. The unbound fraction in rat liver microsomal suspensions (fu, mic) was 
determined in triplicate by ultracentrifugation. The microsomes were suspended in 72.5 mM PBS at 
the same concentration as that used for metabolic stability experiments. The samples for binding 
studies were centrifuged at 436,000g for 4 h at 37°C, and aliquots of the centrifuged upper fraction 
were transferred into 15 volumes of acetonitrile containing IS. Standard samples containing the same 
matrices were prepared, and the unbound compound concentrations in the incubation mixtures were 
quantified using LC-MS/MS. 
Plasma Protein Binding. The unbound fraction in rat plasma (fu, p) was determined in triplicate by 
equilibrium dialysis using a serum binding system (BD Gentest). Plasma samples were spiked with 
the test compound (10 M final concentration), and the device containing plasma and PBS was 
reciprocated in a CO2 incubator at 37°C for 20 h. The resulting PBS samples were transferred into 8 
volumes of acetonitrile containing IS. Standard samples containing the same matrices were prepared, 
and the unbound compound concentration in the plasma was quantified using LC-MS/MS. 
Blood/Plasma Concentration Ratio. The blood/plasma concentration ratio (Rb) was determined in 
vitro after incubation of the compounds with fresh rat blood in duplicate. Blood was warmed to 37°C, 
and the test compound was spiked at a 10 μM final concentration. The blood samples were incubated 
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at 37°C for 5 min and divided into two portions. After centrifugation of the aliquot, the plasma and 
blood samples were transferred into 4 volumes of acetonitrile containing IS, centrifuged, and filtered. 
Standard samples containing the same matrices were prepared, and the compound concentration in 
plasma and blood was quantified by LC-MS/MS. 
Pharmacokinetic Studies in Animals. Raloxifene (1 mg/kg b.wt.) was dissolved in a solution 
containing ethanol, polyethylene glycol 300, and water (1:4:5) as reported previously (Lindstrom et 
al., 1984) and administered intravenously at a volume of 0.5 ml/kg to fasted SD rats, Wistar rats, 
EHBRs, and Gunn rats (n = 3). Blood samples were collected from the animals at 0.05, 0.25, 0.5, 1, 2, 
4, 8, and 24 h after dosing. The plasma samples were separated by centrifugation and stored at −20°C. 
The plasma samples were processed for analysis by protein precipitation with acetonitrile containing 
IS, followed by centrifugation and filtration. Standard samples containing the same matrices were 
prepared, and the compound concentrations in the plasma were quantified using LC-MS/MS. For 
monitoring raloxifene concentrations in portal and systemic plasma after oral administration, SD rats 
cannulated in the portal and jugular vein were used. Raloxifene (2 mg/kg b.wt.) was dissolved in the 
same solution as used for intravenous administration at a volume of 4 ml/kg (n = 3–4), and blood 
samples were collected at 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing. For monitoring drug 
concentrations in portal and systemic plasma after oral administration to EHBRs, Wistar rats, and 
Gunn rats, all animals were sacrificed at five or six time points (n = 3), and blood samples were 
collected. Intravenous (n = 2) or oral (n = 3) administration of raloxifene to beagle dogs was 
conducted using the same solution as that administered to the rats, and pharmacokinetic profile studies 
in cynomolgus monkeys were performed in the same manner (n = 2). When raloxifene was studied in 
dogs, pharmacokinetic parameters before and after cannulation in the portal vein were compared. The 
other UGT substrates, biochanin A (50 mg/kg p.o.), mycophenolic acid (10 mg/kg p.o.), and 
gemfibrozil (30 mg/kg p.o.), were administered to intact SD rats (intravenous) or cannulated SD rats 
(oral) under the same conditions used for raloxifene (n = 3). The preparation of plasma samples was 
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as described above except for gemfibrozil, for which the collected plasma samples were immediately 
transferred to acetonitrile (containing 0.1% formic acid) and IS to avoid degradation of its acyl 
glucuronide. 
Quantification of Glucuronides. The glucuronide concentrations of raloxifene and biochanin A were 
estimated through a hydrolysis assay using β-glucuronidase. The samples were incubated in the 
presence of 250 units of β-glucuronidase at 37°C for 12 to 15 h, and the completion of hydrolysis was 
ascertained by LC-MS/MS analysis. The glucuronide concentration of gemfibrozil was determined by 
UV detection without a hydrolysis assay, in which it was assumed that the UV absorbances of the 
unchanged drug and glucuronide were the same. Because only traces of mycophenolic acid 
glucuronides were detected by UV, these were not quantified. 
LC-MS/MS Analysis. Qualitative analysis for the identification of metabolites was performed using 
an HP1100 system (Agilent Technologies, Santa Clara, CA) equipped with a triple quadrupole Quattro 
Micro mass spectrometer (Waters, Milford, MA). LC conditions were as follows: column temperature, 
40°C; column, CAPCELL PAK MGII (2.0 mm i.d. × 150 mm, 3 μm; Shiseido, Tokyo, Japan); 
gradient elution at 0.2 ml/min, with acetonitrile and 10 mM ammonium acetate; UV detection, 290 
nm; and run time, 20 min. The main working parameters for mass spectrometers were as follows: ion 
mode, electrospray ionization, positive and negative; capillary voltage, 3 kV; cone voltages, 20 and 40 
V; source temperature, 100°C; and desolvation temperature, 350°C. The quantitative analysis for 
unchanged compounds was performed using an Acquity UPLC system equipped with a triple 
quadrupole mass spectrometer (Xevo TQ MS; Waters). UPLC conditions were set as follows: column 
temperature, 50°C; column, Waters Acquity UPLC BEH C18 (2.1 mm i.d. × 30 mm, 1.7 μm); gradient 
elution at 0.5 ml/min, with acetonitrile and 10 mM ammonium acetate; and run time, 3 min. The 
parameters for mass spectrometers were as follows: ion mode, electrospray ionization, positive for 
raloxifene, biochanin A, and mycophenolic acid and negative for gemfibrozil; multireaction 
monitoring method with transitions of m/z 474 3 112 for raloxifene, m/z 285 3 213 for biochanin A, 
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m/z 321 3 159 for mycophenolic acid, and m/z 249 3 121 for gemfibrozil; capillary voltage, 0.5 kV; 
cone voltage and collision energy, 50 V and 30 eV for raloxifene, 50 V and 40 eV for biochanin A, 40 
V and 35 eV for mycophenolic acid, and 20 V and 30 eV for gemfibrozil; source temperature, 150°C; 
and desolvation temperature, 600°C.  
Estimation of Fh, Fa･Fg, and F. Fh was calculated by dividing the systemic plasma AUCs 
(AUCsys) by the portal plasma AUCs (AUCpv) after oral administration to animals. Fa･Fg was 
estimated using eq. 1:  
 
Fa･Fg = Qpv ･ Rb ･ (AUCpv − AUCsys) / dose        (1) 
 
where Qpv is the blood flow in the portal vein, which was assumed to be 70% of the hepatic blood 
flow (Qh) set at 55 ml･min
−1･kg−1 b.wt. for rats or 31 ml･min−1･kg−1 b.wt. for dogs (Davies and 
Morris, 1993). F was calculated by multiplying Fh and Fa･Fg when AUCpv was available. If AUCpv 
was not available, F was calculated by dividing the oral AUC by the intravenous AUC normalized 
with dose. 
IVIVC of UGT Substrates in Rats. Data from incubations with either P450 or UGT cofactors were 
analyzed using a nonlinear single exponential fit, and the CLint values (milliliters per minute per 
milligram of protein) were calculated from the elimination rate constant k, volume of incubation, and 
amount of microsomal protein in incubation. CLint values obtained were corrected for experimentally 
determined fu, mic to give CLint, u and were scaled to the whole-body clearance, CLint, h (milliliters per 
minute per kilogram body weight) for rats using eq. 2: 
 
CLint, h = k･50 mg microsomes/g liver･37.8 g liver/kg b.wt. / (microsomes concentration･fu,mic)  (2) 
 
where 50 mg of microsomes/g liver was a scaling factor (Iwatsubo et al., 1996; Zhou et al., 2002) and 
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37.8 g liver/kg b.wt. was the liver weight used (Luttringer et al., 2003). The observed hepatic 
clearance values after intravenous administration were converted to CLint, iv values using the well 
stirred or parallel tube liver models, defined in eqs. 3 and 4, respectively: 
 
Observed CLint, iv = CLb/fu,p ･ Rb/(1 − CLb/Qh)         (3) 
Observed CLint, iv = − Qh/fu,p ･ Rb ･ ln(1 − CLb/Qh)    (4) 
 
where CLb is the hepatic blood clearance. For biochanin A, the calculated CLb value exceeded the Qh, 
and, therefore, CLb was assumed to be 90% of the hepatic blood flow as reported previously by 
another group (Cubitt et al., 2009). The renal clearance of the four compounds used in this study was 
minor; therefore, hepatic clearance was assumed to be equal to the total clearance. The observed CLint, 
p.o. was calculated from the oral plasma clearance using eq. 5, which assumed complete absorption and 
no intestinal metabolism: 
 
Observed CLint, po = CLpo/fu,p ･ Rb          (5) 
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I-iii. Results 
In Vitro Hepatic and Intestinal Intrinsic Clearance of Raloxifene. The in vitro CLint, u values of 
raloxifene were estimated using liver and intestinal microsomes (XenoTech, LLC) fortified with 
NADPH or UDPGA. The final values were corrected with the free fraction in microsomal incubation 
(fu, mic, 0.278) (Table I-1). The in vitro CLint, u values for glucuronidation determined with intestinal 
microsomes were higher than those with liver microsomes among the tested species, and the values 
using human intestinal microsomes were the highest. In contrast, the in vitro CLint, u values for 
P450-catalyzed metabolism were higher with liver microsomes than with intestinal microsomes for 
these species. The liver and intestinal microsomes were prepared from SD rats, Wistar rats, EHBRs, 
and Gunn rats, and the in vitro CLint, u values of raloxifene were compared. As expected, the in vitro 
CLint, u for glucuronidation determined with Gunn rat microsomes was significantly lower than that 
with Wistar rat microsomes (Figure I-1A). The in vitro CLint, u values for P450 metabolism in 
EHBRs and Gunn rats were lower than those in SD and Wistar rats, respectively (Figure I-1B). 
Pharmacokinetics of Raloxifene. LC-MS/MS analysis with UV detection (290 nm) of the SD rat 
portal plasma samples at 15 min after oral administration of raloxifene resulted in the appearance of 
two glucuronide peaks as major metabolites (Figure I-2). Other metabolites such as sulfated or 
oxidized raloxifene were less. After incubation of this plasma sample in the presence of 
β-glucuronidase, the two major peaks disappeared. The plasma concentration versus time curves of 
raloxifene and its glucuronides in SD rats showed rapid absorption and extensive glucuronidation 
(Figure I-3A). Fa･Fg and Fh in SD rats were estimated to be 0.16 and 0.33, respectively, and the AUC 
ratio of glucuronides to the unchanged drug was 5.73 and 9.67 in the portal and systemic plasma, 
respectively (Table I-2). The pharmacokinetics in Gunn and wild-type Wistar rats exhibited significant 
differences (Figure I-3, B and D). Fa･Fg and Fh in Gunn rats were 0.63 and 0.43, respectively; these 
values were twice those observed (0.34 and 0.20, respectively) in Wistar rats. The AUC ratio of 
glucuronides to unchanged drug in the portal plasma was 2.51 in Wistar rats and 0.03 in Gunn rats. 
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The plasma concentration of raloxifene glucuronides in EHBRs was dramatically higher than that in 
wild-type SD rats (Figure I-3, A and C). The AUC ratio of glucuronides to unchanged drug in EHBRs 
was 46.8 in the portal plasma and 129 in the systemic plasma (Table I-2). The PK parameters of 
raloxifene in beagle dogs were examined before and after implantation of catheters in the portal vein. 
The total clearance and F were similar before and after the cannulation. Fa･Fg and Fh in dogs were 
estimated to be 0.36 and 0.16, respectively (Figure I-3E and Table I-2). F in dogs (0.044 and 0.052) 
was comparable to F in SD rats (0.048), but the AUC ratios of glucuronides to unchanged drug were 
lower in dogs (portal, 0.27; systemic, 1.34) than in rats (portal, 5.73; systemic, 9.67). F in cynomolgus 
monkeys was also comparable (0.030) with those in rats and dogs, but the AUC ratios of glucuronides 
to unchanged drug in systemic plasma were higher in monkeys (85.0) than in rats and dogs (Figure 
I-3F and Table I-2). 
IVIVC of Other UGT Substrates in Rats. The in vitro CLint, u values of biochanin A, mycophenolic 
acid, and gemfibrozil were determined using rat liver and intestinal microsomes (Table I-3).  
The CLint, u values of biochanin A for glucuronidation were extremely high in both rat liver and 
intestinal microsomes. The CLint, u values of mycophenolic acid for glucuronidation were higher in rat 
intestinal microsomes than in rat liver microsomes. In contrast, CLint, u values of gemfibrozil for 
glucuronidation were lower in rat intestinal microsomes than in rat liver microsomes. In all cases, the 
in vitro CLint, u values for P450 metabolism were less than those for glucuronidation. The in vitro 
hepatic CLint, u values for glucuronidation were scaled to whole-body clearance values (milligrams per 
minute per kilogram b.wt.) and were compared with the in vivo CLint values obtained from both 
intravenous and oral pharmacokinetic data (Figure I-4 and Figure AP-1). For calculation of the in vivo 
CLint values, the following Rb, plasma protein binding, and fu, mic values were incorporated. The Rb 
values for gemfibrozil, mycophenolic acid, raloxifene, and biochanin A were 0.56, 0.63, 1.07, and 
0.75, respectively. The plasma protein binding values for these compounds were 98.9, 99.2, 99.4, and 
98.8%, respectively. The fu, mic values for these compounds were 0.907, 0.776, 0.278, and 0.600, 
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respectively. The IVIVC from intravenous clearance values was relatively good, but the CLint, h values 
of raloxifene and biochanin A obtained from the oral pharmacokinetic data were significantly 
underestimated, supporting the contribution of intestinal metabolism to a first-pass effect. Fa･Fg and 
Fh of biochanin A, mycophenolic acid, and gemfibrozil were examined after oral administration to SD 
rats (Table I-4). Biochanin A, which is susceptible to extremely high glucuronidation, exhibited low 
Fa･Fg (0.15), whereas gemfibrozil and mycophenolic acid, compounds with relatively low CLint for 
glucuronidation, demonstrated high Fa･Fg (1.40 and 1.17, respectively). 
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I-iv. Discussion 
Conjugation reactions have been increasingly recognized as important metabolic processes 
that play a strong role in the pharmacokinetics of some drugs; therefore, prediction of the clearance of 
such drugs is necessary. However, unlike that for P450 substrates, the IVIVC for UGT substrates has 
not been studied adequately because the amount of UGTs expressed in tissues is uncertain, and the 
intraluminal localization of the catalytic sites, which require activation for in vitro glucuronidation, 
makes IVIVC more complex (Lin and Wong, 2002). UGTs are widely expressed in various tissues 
including the liver, kidney, and gastrointestinal tract (Ohno and Nakajin, 2009), and the importance of 
extrahepatic glucuronidation has been reported (Ritter et al., 2007). Flavonoids (polyphenolic 
phytochemicals) were used as model UGT substrates in several studies in which not only hepatic but 
also intestinal glucuronidation and subsequent excretion by efflux transporters were reported (Jia et al., 
2004; Zhang et al., 2007). 
Raloxifene also has phenolic groups, and its oral bioavailability in humans is very low 
because of a high glucuronidation rate catalyzed by UGT1A8 and 1A10 in the intestine (Kemp et al., 
2002; Jeong et al., 2005; Mizuma, 2009); its conjugates are subsequently excreted into the gut lumen 
by P-glycoprotein and/or MRPs. These enzyme and transporter couplings are thought to result in long 
half-lives because of enteric recycling despite the extensively high oral clearance (Jeong et al., 2004; 
Xu et al., 2009). 
In the present study, species differences in CLint, u for in vitro glucuronidation of raloxifene 
were investigated (Table I-1), and the results were compared with its pharmacokinetics (Table I-2). To 
activate UGT, alamethicin was used as a pore-forming agent according to previous reports (Dalvie et 
al., 2008; Cubitt et al., 2009). The results were consistent with those reported by others, for which the 
glucuronidation rates with rat or human intestinal microsomes were higher than those with rat or 
human liver microsomes. Our study also showed that all the CLint, u values among investigated 
animals were higher for glucuronidation than for P450 metabolism in intestinal microsomes. The  
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CLint, u values obtained with dog liver or intestinal microsomes were comparable to those with rat liver 
or intestinal microsomes. Comparing these in vitro CLint, u values with the Fa･Fg and Fh values in the 
two animals demonstrated a reasonable relationship. In humans and monkeys, the raloxifene 
concentrations in portal plasma were not available; therefore, Fa･Fg was calculated from intravenous 
and oral pharmacokinetic data (total clearance in human = 0.647 l･h−1･kg−1; Eli Lilly clinical data) by 
assuming Fh = 1 − CLb/Qh and Fa･Fg = F/Fh. When Qh values in humans and monkeys were set at 
20.7 and 43.6 ml･min−1･kg−1 (Davies and Morris, 1993), the calculated Fa･Fg values were 0.045 and 
0.041, respectively. The Fa of raloxifene in humans was reported as 0.63 (Eli Lilly clinical data), and 
its permeability was high in our in-house study using Caco-2 cells (data not shown). Therefore, 
intestinal glucuronidation must be a main factor contributing to the first-pass effect. 
In the present study using Gunn and Wistar rats, it was suggested that raloxifene was 
glucuronidated mainly by UGT1As and to lesser extent by UGT2Bs (Figure I-3, B and D; Table I-2) 
because Gunn rat inherently lacks all glucuronidation activities catalyzed by the UGT1 isoforms due 
to mutation in exons II, commonly used region for the these isoforms (Emi, 2002). The Fa･Fg and Fh 
values in Gunn rats were 2-fold higher than those in Wistar rats, respectively, indicating that 
raloxifene was glucuronidated in the intestine as well as in the liver. In the comparison of EHBRs 
with SD rats (Figure I-3, A and C), the differences in Fa･Fg and Fh were small, and the ratio of 
glucuronides to unchanged drug in systemic plasma was much higher in EHBRs, suggesting that the 
excretion of raloxifene glucuronides was influenced by Mrp2. Some groups have reported a 
compensatory induction of enzymes and transporters in Gunn and Mrp2-deficient TR
− 
rats (Kim et al., 
2003; Wang et al., 2009). Flavonoids such as apigenin are efficiently metabolized by Gunn rats 
because of compensatory induction of intestinal UGT 2Bs and hepatic efflux transporters, which 
limits their oral bioavailabilities. In our studies, CLint, u values for P450 metabolism determined with 
liver microsomes from Gunn rats and EHBRs were lower than those from Wistar and SD rats (Figure 
I-2); therefore, P450s responsible for the oxidation of raloxifene did not show compensatory induction. 
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CLint, u values for glucuronidation determined with microsomes from Gunn rats were lower than those 
from Wistar rats; implying that UGTs responsible for glucuronidation of raloxifene were not induced. 
Of interest, species differences in the ratio of glucuronides to unchanged drugs were observed despite 
comparable CLint, u values for glucuronidation in dogs, rats, and monkeys. These ratios in the systemic 
plasma in dogs, SD rats, and monkeys were 1.34 to 1.84, 9.67, and 85.0, respectively, and the ratio in 
humans was reported as 70 to 90 (Eli Lilly clinical data). The ratios in monkeys and humans were 
closer to those in EHBRs than to those in wild-type SD rats, indicating that hepatic uptake of 
raloxifene glucuronides into the liver and excretion of them into intestinal lumen and bile may 
significantly differ among these species. Expression of Mrp2/MRP2 in rat, dog, and human intestine 
has been reported (Mottino et al., 2000; Conrad et al., 2001), but species differences in transport 
activity of raloxifene glucuronides have not been reported. A schematic representation of the intestinal 
and hepatic disposition of raloxifene is presented in Figure I-5. Further studies are needed to 
understand the differences in raloxifene glucuronide levels in circulation after administration in these 
species. 
The in vitro hepatic CLint, u values of raloxifene, biochanin A, mycophenolic acid, and 
gemfibrozil (Table I-3) for glucuronidation were scaled to whole-body clearances (milligrams per 
minute per kilogram body weight) and compared with their observed in vivo CLint values (Figure I-4; 
Table I-4). These compounds have been reported to be mainly excreted in bile as glucuronides in rats 
(Curtis et al., 1985; Jia et al., 2004; Takekuma et al., 2007). Therefore, their total clearance values 
were assumed to be nearly equal to their hepatic clearance values. CLint, h values could be predicted 
quite well from the in vitro hepatic CLint, u values for glucuronidation except for raloxifene. The CLint, 
u value of raloxifene with rat liver microsomes in the presence of NADPH was comparable to that in 
the presence of UDPGA; this underestimation may be caused by the exploration that did not 
incorporate P450-catalyzed metabolism into hepatic clearance. The oral clearance values for 
raloxifene and biochanin A were much higher than the predicted values, implying that intestinal 
  
20 
 
glucuronidation was a great contributor. The in vitro intestinal CLint, u values for glucuronidation 
relatively corresponded to the Fa･Fg values for the four compounds investigated. Biochanin A is also 
a human UGT1A10 substrate, which is considered to be an important isoform in the gastrointestinal 
tract (Lewinsky et al., 2005). With regard to this compound, much less is known about the intestinal 
effect on presystemic elimination in humans and the responsible UGT isoforms in rats. There are 
several publications on IVIVC for UGT substrates (Kilford et al., 2009; Miners et al., 2010). It is well 
known that in vitro predictability of CLint depends on enzyme sources, experimental conditions, and 
the occurrence of atypical glucuronidation kinetics. In some cases, in vitro CLint values using 
microsomes were underestimated in comparison with in vivo values. It was reported that addition of 
BSA to the incubation improved the predictability from microsomal data, in particular for UGT2B7 
substrates (Rowland et al., 2007, 2008). However, Kilford et al. (2009) reported that the human CLint 
value of gemfibrozil, a UGT 2B7 substrate, was overestimated 10-fold when BSA was added to the 
microsomal incubation. In the present study, the rat CLint value of gemfibrozil was successfully 
predicted using rat liver microsomes in the absence of BSA. Rat UGT isoforms responsible for 
glucuronidating gemfibrozil and their selectivity of substrates have not been fully elucidated; 
therefore, further studies are needed using recombinant UGT isozymes or specific antibodies. 
β-glucuronidase activity also influences on glucronidation rate in in vitro experiment. Oleson reported 
(2008) that typical inhibitor saccharolactone had minor effect on hydrolysis rate of glucuronides and 
inhibitory effect on glucuronidation rate at high concentration, therefore experimental condition 
should be cautiously considered if β-glucuronidase inhibitors are used. In several studies, models for 
Fg prediction of drugs, particularly for CYP3A substrates, which are metabolized in the small 
intestine, have been proposed (Galetin and Houston, 2006; Yang et al., 2007; Gertz et al., 2010; 
Kadono et al., 2010). These approaches were recently applied to UGT substrates (Nakamori, 2012; 
Wu, 2013). In the present study, Fg for four compounds estimated from in vitro intestinal CLint values 
by Qgut model  (Yang, 2007) correlated well with observed Fa･Fg (Figure AP-2). These findings 
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indicate that evaluation of intestinal glucuronidation using microsomes is useful for determination of 
intestinal availability.  
In most pharmaceutical companies, NCEs not susceptible to P450-catalyzed metabolism 
have been eagerly investigated and synthesized by introducing hydrophilic groups into their structures. 
Therefore, prediction of Fg for such compounds, which are often eliminated through phase II 
metabolism and subsequent excretion, is becoming essential. For anionic compounds, the interactions 
of conjugating enzymes with transporters have been increasingly recognized as an important process 
of elimination (Nies et al., 2008; Pang et al., 2009; Sun et al., 2010). Therefore, comprehensive 
studies including metabolism and transport are required. 
 
  
  
22 
 
I-v. Conclusion 
The impact of intestinal glucuronidation on the pharmacokinetics of UGT substrates was 
investigated by in vitro and in vivo methods. The IVIVC of four Ugt substrates (raloxifene, biochanin 
A, gemfibrozil, and mycophenolic acid) in rats using data from liver microsomes and CLint, iv 
displayed a good relationship, but the CLint, po of raloxifene and biochanin A, which were extensively 
glucuronidated by intestinal microsomes, were higher than the predicted values using data from only 
liver microsomes, indicating that intestinal metabolism may be a great contributor to the first-pass 
effect. The in vitro intestinal CLint corresponded with Fa･Fg for four Ugt substrates examined in rats. 
In Gunn rats, Fa･Fg and Fh of raloxifene were twice those observed in wild-type rats, indicating that 
raloxifene was mainly glucuronidated by Ugt1As in both the intestine and the liver. The difference in 
contribution of intestinal and hepatic glucuronidation of raloxifene to the first-pass effect between rats 
and dogs was demonstrated. These findings suggest that the evaluation of intestinal and hepatic 
glucuronidation for NCEs is important to improve their pharmacokinetic profiles. 
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Figure I-1. The CLint, u of raloxifene metabolism (milliliters per minute per milligram of protein) 
in rat microsomes.  
 
Microsomal incubations were fortified with A) UDPGA or B) NADPH. 
■, CLint, u by liver; □, CLint, u by intestinal microsomes.  
Each column represents the mean and error bars indicate the S.D. 
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Figure I-2. HPLC chromatograms with UV detection at 290 nm of raloxifene and its 
metabolites. 
 
A) rat blank plasma and B) portal plasma at 15 min after dosing raloxifene (2 mg/kg p.o.) to SD rats. 
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Figure I-3. Plasma concentration versus time profiles of raloxifene and its glucuronides after 
oral administration.  
 
Closed symbols ■, systemic plasma concentrations; open symbols □, portal plasma concentrations.  
▲ and ∆, raloxifene; ■ and □, glucuronides.  
Raloxifene was dissolved in ethanol, polyethylene glycol 300, and water (1:4:5) and administered at 2 
mg/kg to A) SD rats, B) Wistar rats, C) EHBRs, D) Gunn rats, E) beagle dogs, and F) cynomolgus 
monkeys. Each symbol represents the mean and the error bars indicate the S.D. 
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Figure I-4. Comparison of predicted and observed CLint, h values in SD rats.  
 
CLint, h values were predicted using rat liver microsomes fortified with UDPGA. A) comparisons of 
predicted and observed CLint, h values from intravenous pharmacokinetic data obtained from the well 
stirred (open) and parallel tube (closed) liver models for four compounds. B) comparison of predicted 
and observed CLint, h values from oral pharmacokinetic data that assumed complete absorption and no 
intestinal metabolism. Dashed lines represent Y = X. 
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Figure I-5. Schematic representation of intestinal and hepatic disposition of raloxifene 
 
S, raloxifene; G, glucuronic acid; P-gp, P-glycoprotein. 
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Table I-1. CLint, u of raloxifene metabolism by rat, dog, monkey, and human liver and intestinal 
microsomes.  
 
 
 
Microsomal incubations were fortified with UDPGA or NADPH. CLint, u values represent the mean ± 
S.D. of three determinations. 
 
 
  
Rat 0.359 ± 0.038    0.992 ± 0.099    0.293 ± 0.096    0.019 ± 0.007    
Dog 0.693 ± 0.086    1.344 ± 0.088    0.884 ± 0.033    0.092 ± 0.012    
Monkey 0.289 ± 0.075    1.737 ± 0.692    0.386 ± 0.027    0.375 ± 0.009    
Human 0.470 ± 0.051    3.284 ± 0.268    0.119 ± 0.022    0.028 ± 0.008    
CLint, u
LiverLiver Intestine
UGT
Intestine
P450
ml ･min -1･mg protein -1
Microsomes
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Table I-2. Pharmacokinetic parameters of raloxifene after intravenous or oral administration to 
SD rats, EHBRs, Wistar rats, Gunn rats, beagle dogs, and cynomolgus monkeys 
 
 
 
If AUCpv was not available (intact dogs and monkeys), F was calculated by dividing the oral AUCs 
by the intravenous AUCs corrected for dose. Values in parentheses represent S.D.s. 
 
 
  
Animals
Portal Systemic
ml ･ h -1･ kg -1 ml/kg ng ・ h/ml ng /ml ng ・ h/ml
SD rats 2051 (172) 3240 (440) 490 (42) 11.4 (0.7) 58.3 (15.2) 5.73 (1.14) 9.67 (4.65） 0.33 (0.11) 0.16 (0.08) 0.048 (0.014)
EHBRs 1323 (153) 3673 (499) 762 (84) 14.5  160 46.8 129 0.43    0.26    0.11   
Wistar rats 1475 (323) 4015 (1673) 704 (176) 13.0  68.2  2.51   3.80   0.20    0.34    0.067   
Gunn rats 1305 (158) 4967 (595) 775 (100) 45.2  389 0.03   0.09   0.43    0.63    0.27   
Dogs
 Intact 1057     3157     976 16.0 (2.3) 85.7 (15.6) N.D. 1.84 (0.61) N.D. N.D. 0.044 (0.008)
 Cannulated 1163     3022     860 23.3 (1.4) 87.4 (20.9) 0.27 (0.10) 1.34 (0.52) 0.16 (0.04) 0.36 (0.18) 0.052 (0.014)
Monkeys 909     3847     1102 6.0  62.2  N.D. 84.98   N.D. N.D. 0.026   
N.D., not determined.
Cmax AUC
1 mg/kg i.v. 2 mg/kg p.o.
Glu/Parent ratio
Fh Fa･Fg FCLtot Vdss AUC
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Table I-3. CLint, u of gemfibrozil, mycophenolic acid, raloxifene, and biochanin A metabolism by 
rat liver and intestinal microsomes.  
 
 
 
Microsomal incubations were fortified with UDPGA or NADPH. CLint, u values represent the mean ± 
S.D. of three determinations. 
 
  
Gemfibrozil 0.273 ± 0.008    0.001 ± 0.002    0.025 ± 0.008    0.002 ± 0.002    
Mycophenolic acid 0.042 ± 0.006    0.229 ± 0.014    0.006 ± 0.003    0.002 ± 0.001    
Raloxifene 0.359 ± 0.038    0.992 ± 0.099    0.293 ± 0.096    0.019 ± 0.007    
BiochaninA 5.050 ± 0.744    2.845 ± 0.234    0.062 ± 0.004    0.004 ± 0.004    
Intestine
ml ･min -1･mg protein -1
Microsomes
CLint, u
UGT P450
Liver Intestine Liver
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Chapter II 
 
 
Hepatic uptake and biliary excretion of raloxifene glucuronide and the 
other compounds 
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II-i. Introduction  
In the chapter I, we observed that the blood concentration ratio of raloxifene glucuronides to 
the parent drug was greater in EHBRs (129) than that in SD rats (10). The blood concentration ratio of 
raloxifene glucuronides to the parent drug in humans is as high as 70–90 (Eli Lilly clinical data), a 
value similar to that in EHBRs. The glucuronidation activities of the liver and intestinal microsomes 
for raloxifen were comparable between these two rat strains, suggesting that an alteration of 
metabolism could not explain the difference in glucuronide exposure between SD rats and EHBRs 
(Kosaka et al., 2011). The simplest interpretation is that raloxifen glucuronides are transport substrates 
of Mrp2 and that its genetic deficiency in EHBR results in the accumulation of these conjugates in 
hepatocytes that then flow back into the blood. In line with this interpretation, the expression of 
MRP2 in normal human liver is considerably lower than that in SD rat liver (Ninomiya et al., 2005; Li 
et al., 2009). However, secondary alteration in sinusoidal transporters expression and/or the inhibition 
of their function by endogenous substances such as bilirubin glucuronides (Mrp2 substrate, Cui et al., 
2001), possibly exaggerate the phenotypic differences between SD rats and EHBRs or between 
experimental animals and humans. The induction of Mrp3 (a sinusoidal efflux transporter of organic 
anions) and down-regulation of Oatp1a1 and Oatp1a4 (sinusoidal uptake transporters of organic 
anions) are observed in EHBRs (Kuroda et al., 2004). Moreover, MRP3 is highly expressed in the 
normal state in human liver (Ohtsuki et al., 2012; Chu et al., 2013), so that it is important to determine 
whether the phenotypic difference observed in EHBR is attributable solely to Mrp2 deficiency or also 
to other effects. Such generic interpretation, not restricted to Mrp2/MRP2, would improve the 
predictability of the in vivo disposition of organic anions in humans based on that in rats. 
In the present study, we focused particularly on the pharmacokinetic differences of organic 
anions including R6G between SD rats and EHBRs to determine whether they could be explained 
solely by a difference in its biliary excretion process, and conducted further investigation into a 
hepatic uptake process. 
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II-ii. Materials and Methods 
Reagents. [
14
C]raloxifene (59 mCi/mmol, 99%) was purchased from Perkin Elmer (Boston, MA). 
Raloxifene-6-glucuronide (R6G) was obtained from Toronto Research Chemicals (Toronto, Canada). 
Non-labeled estradiol-17β-glucuronide (E217βG) and [
3
H] E217βG (34 Ci/mmol, 97%) were 
purchased from Sigma-Aldrich and Perkin Elmer, respectively. valsartan was obtained from Wako 
(Osaka, Japan). Human intestinal microsomes were obtained from XenoTech, LLC (Lenexa, KS). The 
UGT reaction mix solution (250 mM Tris-HCl, 40 mM MgCl2, and 0.125 mg/ml alamethicin) was 
purchased from BD Gentest (Woburn, MA). Rat Mrp2 and control vesicle (insect Sf9 
cells/baculovirus systems expressing transporters) and a vesicular transport assay reagent kit were 
purchased from Geno Membrane (Kanagawa, Japan). All chemicals were of analytical grade or the 
highest quality available.  
Animals. All animal procedures were conducted under protocols approved by the Mitsubishi Tanabe 
Institutional Animal Care and Use Committee. Male SD rats and EHBRs 7 to 8 weeks old were 
obtained from Japan SLC (Shizuoka, Japan).  
Synthesis of [
14
C]R6G. [
14
C]Raloxifene was glucuronidated using human intestinal microsomes 
fortified with UDPGA (a UGT reaction mix solution). The resulting [
14
C] R6G was purified by 
high-pressure liquid chromatography (HP1100 system; Agilent Technologies, Santa Clara, CA) on a 
column (Symmetry C18; 3.5 µm particle size, 4.6 mm i.d. × 150 mm, Waters) with isocratic elution 
using acetonitrile and 10 mM ammonium acetate and desalted with salt-free mobile phase. [
14
C] R6G 
was identified by comparison with unlabeled synthetic standards using a liquid chromatography–mass 
spectrometer/mass spectrometer (LC-MS/MS) system (Quattro Micro, Waters, Milford, MA). 
Vesicular Transport Assays. The time- and concentration-dependent transport of [
14
C] R6G into rat 
Mrp2-expressing membrane vesicles and control membrane vesicles (insect Sf9 cells/baculovirus 
systems) was investigated according to the manufacturer’s instructions (Geno Membrane) using the 
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rapid filtration technique. In brief, the transport medium (final, 10 mM MOPS-Tris, 14 mM KCl, 4 
mM MgATP (or MgAMP) and 2 mM GSH, pH 7.4) containing R6G (time-dependent transport, 
0.625μM; concentration-dependent transport, 0.625, 1.25, 2.5, 5, 7.5, 12.5, 25, 37.5, and 50 μM) was 
mixed with the vesicle suspension. At a designated time (time-dependent transport, 1, 3, 5, and 10 
min; concentration-dependent transport, 3 min), the transport reaction was stopped by the addition of 
an ice-cold buffer (40 mM MOPS-Tris, 70 mM KCl, pH 7.4) and filtered (MulitiScreen, Millipore). 
The filters were washed with the same ice-cold buffer three times. The radioactivity retained on the 
filters was analyzed with a liquid scintillation counter (TRI-CARB 3100TR, Perkin Elmer). 
ATP-dependent uptake into vesicles was calculated by subtracting data generated with AMP from ATP 
data, and resulting values for control vesicles were subtracted from those for Mrp2-expressing 
vesicles to estimate Mrp2-specific transport. 
Pharmacokinetic Studies of R6G. R6G (0.5 μmol/kg) was intravenously administered to bile 
duct-canulated rats (n = 3). Blood was collected at 0.05, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h after 
administration. Bile was accumulated at the designated time periods (0‒0.25, 0.25‒0.5, 0.5‒1, 1‒2, 2‒
4, 4‒8, and 8‒24 h) after administration. The plasma was separated from the blood by centrifugation. 
The plasma and bile samples were processed for analysis by protein precipitation with acetonitrile. 
Standard samples containing the same matrices were prepared, and the compound concentrations were 
quantified by LC-MS/MS. Total clearance (CLtotal) was calculated as dose/AUC. Vdss was calculated 
as the product of CLtotal and MRT obtained by moment analysis. Biliary clearance (CLbile) based on 
plasma concentration was calculated as the product of excretion rate and CLtotal. 
Integration Plot Studies in the Rat Liver. Three compounds (R6G, 0.1 μmol/kg; valsartan, 0.5 
μmol/kg; E217βG, 0.5 μmol/kg) were intravenously administered to rats (n = 3) each. Blood was 
collected at 1 min, 3 min, and 5 min after administration and the liver was isolated at the final point. 
The plasma was separated from the blood by centrifugation. The liver was homogenized with saline 
and acetonitrile and centrifuged, and the protein precipitate was removed. Standard samples 
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containing the same matrices were prepared, and the compound concentrations were quantified by 
LC-MS/MS. Hepatic uptake clearance was calculated from the slope of an integration plot. 
Compartmental Pharmacokinetic Modeling of R6G Disposition in Rats in vivo. Compartmental 
pharmacokinetic modeling was performed using NAPP version 2.31 software (Hisaka and Sugiyama 
1998). Five kinetic parameters, including the volume of distribution (S1), elimination rate constant 
(ke), hepatic uptake rate constant (k12), sinusoidal efflux rate constant (k21), and biliary excretion rate 
constant (kbile), were estimated (Figure II-1). In this model, R6G is assumed to distribute mainly in 
liver as a peripheral compartment. Although a peripheral compartment may be influenced by an 
extra-hepatic organ, it was excluded because separation of hepatic and extra-hepatic compartments 
was difficult. 
Statistics. Data were analyzed using Microsoft Excel 2010. Statistical significances were tested by the 
two-tailed Student’s t test. Probability (P) values are symbolized by: * = P < 0.05, ** = P < 0.01, and 
*** = P < 0.001. P < 0.05 was considered statistically significant. 
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II-iii. Results 
Vesicular Transport Assays. The transport of [
14
C] R6G was evaluated using rat Mrp2 
expressing-membrane vesicles. ATP-dependent uptake was enhanced in Mrp2-expressing vesicles as 
compared to the control vesicles (Figure II-2A). ATP-dependent uptake into Mrp2-expressing vesicles 
was time-dependent. Uptake was linear during at least the initial 5 min. The concentration dependence 
of the initial 5-min uptake was evaluated and Mrp2-dependent uptake was calculated by a subtraction 
of the uptake into control vesicles (possibly mediated by endogenous transporters expressed in Sf9 
cells) from that into Mrp2-expressing vesicles in the presence of ATP, and plotted as an Eadie–Hofstee 
plot (Figure II-2B). The uptake of [
14
C] R6G by rat Mrp2-expressing membrane vesicles exhibited a 
two-phase kinetic profile. The higher-affinity Km of 1.9 µM was obtained, but the lower component 
was not calculated, at least under our experimental conditions (R6G concentration range of 0.625–50 
μM). Uptake of [14C] R4’G, major metabolite of raloxifene in human, into human MRP2- and MRP3- 
expressing membrane vesicles was also enhanced in the presence of ATP (Figure AP-4). 
In vivo Disposition of R6G in SD rats and EHBRs. Concentrations of R6G in plasma and bile after 
the intravenous administration of R6G (0.5 μmol/kg) to bile duct-canulated SD rats and EHBRs 
showed clear differences from each other (Figure II-3). The model-independent parameters are shown 
in Table II-1. CLtotal and biliary efflux clearance (CLbile) of R6G based on plasma concentration were 
significantly decreased in EHBR as compared to that in SD rats. These findings are consistent with 
the function of R6G as a transport substrate of Mrp2 (Figure II-2).  
Compartmental Pharmacokinetic Modeling of R6G Disposition in Rats in vivo. Time profiles of 
R6G plasma concentration and R6G cumulative biliary amounts in rats were fitted to the 
two-compartment model shown in Figure II-1. As a result, significant decreases not only in biliary 
excretion, which are likely to be attributable to the Mrp2-mediated transport process (kbile), but also in 
the hepatic uptake process (k12) were observed in EHBRs (Table II-2). To ascertain whether the 
reduction in hepatic uptake generally occurs in EHBRs, two-compartment models for the other Mrp2 
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substrates valsartan and E217βG were fitted, using literature data reported by Yamashiro (2006) and 
Morikawa (2000), respectively. Thus, the hepatic uptake of valsartan was much lower in EHBRs than 
that in SD rats. In contrast, the hepatic uptake of E217βG was comparable between SD rats and 
EHBRs (Table AP-1 and Figure AP-3). 
Integration Plot Studies in the Rat Liver. An integration plot study of R6G (0.1 μmol/kg) in the 
liver was conducted in SD rats and EHBRs. As expected from the data in pharmacokinetic modeling, 
hepatic uptake clearance of R6G was significantly lower (with a 66% reduction) in EHBRs than that 
in SD rats (Figure II-4A and Table II-3). This result indicated that Mrp2 deficiency collaterally 
attenuated the hepatic uptake of R6G. Moreover, integration plot studies of valsartan (0.5 μmol/kg) 
and E217βG (0.5 μmol/kg) were conducted. As a result, the hepatic uptake clearance of valsartan was 
lower (with a 95% reduction) in EHBRs than that in SD rats, whereas the hepatic uptake clearance of 
E217βG was similar between the rat strains (Figure II-4B, 4C and Table II-3). 
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II-iv. Discussion  
In the present study, we confirmed that biliary excretion of R6G is mediated by Mrp2 
through the three experiments: 1) uptake into Mrp2-expressing membrane vesicles (Figure II-2), 2) 
compartmental pharmacokinetic modeling after bolus injection (Figure II-3 and Table II-2), and 3) 
biliary clearance under steady state after intravenous infusion (Figure AP-5 and Table AP-2). In the 
analysis of compartmental pharmacokinetic modeling of R6G, we unexpectedly observed that the 
hepatic uptake rate constant (k12) was significantly reduced in EHBRs as compared to SD rats in 
addition to the reduction in the biliary excretion rate constant (kbile). The reduction in hepatic uptake 
clearance of R6G in EHBRs was confirmed by the integration plot analysis (Figure II-4A and Table 
II-3). To ascertain whether the reductions in hepatic uptake generally occur in EHBRs, literature data 
of organic anions including plasma and bile concentration in SD rats and EHBRs were collected and 
classified based on the difference in initial distribution between these rats (Table AP-3). The 
pharmacokinetics of valsartan in SD rats and EHBRs were reported by Yamashiro et al. (2006). Our 
analysis by the two-compartment modeling for valsartan using their data suggested that not only kbile 
but also the k12 were much reduced in EHBRs as compared to those in SD rats (Table AP-1 and Figure 
AP-3A, B). This finding is consistent with the results of our integration plot analysis (Figure II-4B 
and Table II-3). The pharmacokinetics of E217βG after intravenous administration in SD rats and 
EHBRs were reported at the tracer level (Morikawa et al., 2000). As shown in Table AP-1 and Figure 
AP-3C and D, our analysis by the two-compartment modeling for E217βG using their data indicated 
that k12 values were comparable between SD rats and EHBRs. It is also accordant with the result of 
integration plot analysis shown in this study (Figure II-4C and Table II-3). The plasma concentrations 
at 1 min in SD rats and EHBRs in integration plot studies were as follows: R6G, 0.88 ± 0.09 μM and 
1.44 ± 0.25 μM; valsartan, 8.1 ± 0.4 μM and 11.5 ± 0.6 μM; E217βG, 2.9 ± 0.5 μM and 3.7 ± 1.0 μM, 
respectively. The liver concentrations at 1 min in SD rats and EHBRs in these studies were as follows: 
R6G, 0.59 ± 0.10 μM and 0.47 ± 0.13 μM; valsartan, 5.4 ± 0.9 μM and 0.85 ± 0.28 μM; E217βG, 8.3 
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± 0.8 μM and 4.6 ± 1.0 μM, respectively. The free fraction of R6G in SD rat and EHBR plasma were 
0.038 ± 0.011 and 0.042 ± 0.009, respectively. The free fraction of R6G in SD rat and EHBR liver 
were 0.051 ± 0.004 and 0.058 ± 0.011, respectively. Comparable plasma concentrations between these 
rats imply that the saturation in hepatic uptake did not occur in EHBRs, even if free fraction of the 
compound concentration is not taken into consideration. However further examination of dose 
dependency is needed to exclude the possibility of the saturation in hepatic uptake of these 
compounds. It is known that E217βG is transported by Oatp1a1, Oatp1a4, and Oatp1b2 on the 
sinusoidal membrane of hepatocytes in rats, and the Km values have been reported to be 3–20, 3, and 
32 μM, respectively (Hagenbuch et al., 2003). The reason why the hepatic uptake of organic anions is 
decreased for some compounds but not for others in EHBR is unclear at present. One reason for the 
difference may be that the substrate specificities of these transporters overlap to some extent but are 
not identical, and that expression and/or function of those are differentially affected in EHBR. Kuroda 
et al. (2004) reported that the hepatic expression of Mrp3 was induced and those of Oatp1a1 and 
Oatp1a4 protein were reduced adaptively in EHBRs by a compensatory mechanism for mitigating 
injury to hepatocytes from cytotoxic materials that increase in Mrp2 deficiency. In our preliminary 
study, the in vitro uptake into freshly isolated hepatocytes from SD rats and EHBRs exhibited no 
difference for any of the compounds tested (Figure AP-6 and 7). The discrepancy between the in vivo 
and in vitro results may have been due to the suppression of transporter function and/or expression 
during the isolation of hepatocytes from SD rats. Lundquist et al. recently reported (2014a, b) the 
impact of transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. They 
found that rat Oatp2b1 protein was significantly reduced after cell isolation and further after 
cryopreservation, compared with liver tissue. In their study, the hepatic uptake clearance was 
somewhat underestimated when fresh hepatocytes were used. In addition to the down-regulation of 
the amount of transporters in the cells, internalization of the transporters from the cell surface is also 
possible. It has been reported that human OATP2B1 and OATP1B3 are rapidly internalized by the 
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protein kinase C activator, phorbol- 12-myristate-13-acetate (PMA) (Köck et al, 2010; Powell et al, 
2014). This possibility remains to be elucidated in future. Another hypothesis explaining the 
difference in pharmacokinetics between SD rats and EHBRs is the inhibition of the transport function 
by endogenous substances such as bilirubin glucuronides. Bilirubin glucuronide (direct bilirubin) 
concentration in plasma was reported to be as high as 49.1 μM in EHBR, whereas that in SD rat was 
only 1.05 μM (Sathirakul et al., 1993). It has been reported that rat Oatp1a1 accepts bilirubin 
monoglucuronide as a transport substrate, but rat Oatp1a4 does not (Reichel et al., 1999), and that the 
Km values for human OATP1B1 and OATP1B3 were 0.10 and 0.50 μM, respectively (Cui et al., 
2001). We preliminarily tested this hypothesis by comparing the effects of SD rat plasma and EHBR 
plasma (50% and 95%, each) on the transport of [
14
C]R6G into isolated hepatocytes prepared from SD 
rats (Figure AP-8). Both plasma similarly reduced the uptake of [
14
C]R6G into hepatocytes and 
showed no differences, at least under our experimental conditions. The effect independent of the 
plasma of rat strains is likely attributable to a decrease in the unbound concentration of [
14
C]R6G in 
the presence of plasma protein. The binding of R6G to plasma protein in both rat strains is so high as 
described above, that reduction of the unbound concentration of R6G in the transport medium 
obscured the inhibitory effect of bilirubin glucuronide in EHBR plasma on the uptake of R6G into 
hepatocytes. An understanding of the mechanism explaining the difference in hepatic uptakes of 
organic anions between SD rats and EHBRs awaits further investigation. 
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II-v. Conclusion 
The hepatic uptake and biliary excretion process of organic anions in SD rats and EHBRs 
were investigated. R6G was confirmed to be a substrate of MRP2/Mrp2 by in vitro and in vivo 
methods. Pharmacokinetic modeling of R6G indicated that reduction in not only biliary excretion but 
also hepatic uptake of R6G influenced to low plasma clearance in EHBRs compared to SD rats. The 
reduction in hepatic uptake of R6G in EHBRs was confirmed by integration plot study. The reduction 
was also observed for valsartan but not for E217βG. This variation may be related to the difference in 
substrate specificity of organic anion transporters and/or inhibition of hepatic uptake by endogenous 
substances such as bilirubin glucuronides. Incidental alteration of hepatic uptake for organic anions 
should be considered to explain their enhanced systemic exposure in EHBRs. This finding is 
important for a better prediction of the drug disposition in humans based on animal or in vitro uptake 
experiments. 
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Figure II-1. Compartmental pharmacokinetic modeling 
 
S1, ke, k12, k21, and kbile represent the volume of distribution, elimination rate constant, hepatic uptake 
rate constant, sinusoidal rate efflux constant, and biliary excretion rate constant, respectively. 
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Figure II-2. Time- and concentration-dependent transport of [
14
C] R6G into rat 
Mrp2-expressing membrane vesicles.  
 
A) Time-dependent uptake of [
14
C] R6G into rat Mrp2-expressing membrane vesicles and control 
membrane vesicles in the presence of ATP/AMP. Closed and open symbols represent rat 
Mrp2-expressing membrane vesicles and control membrane vesicles, respectively. Square and 
triangular symbols represent the reactions with ATP and AMP, respectively. B) Eadie–Hofstee plot of 
[
14
C] R6G uptake by rat Mrp2 membrane vesicles. Mrp2-dependent uptake was calculated by a 
subtraction of the uptake into control vesicles from that into Mrp2-expressing vesicles. 
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Figure II-3. Compartmental pharmacokinetic modeling of R6G after bolus injection (0.5 
μmol/kg) in rats. 
 
Individual time profiles of R6G plasma concentration in A) SD rats and B) EHBRs, and R6G 
cumulative biliary amounts in C) SD rats and D) EHBRs were fitted to the two-compartment model 
shown in Figure 1. Closed and open symbols represent plasma concentration and cumulative biliary 
excretion, respectively. Circular, square, and triangular symbols represent the individual values 
observed. Solid, dotted, and dashed lines represent the individual time-concentration curves 
simulated. 
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Figure II-4. Integration plots of Mrp2 substrates in the rat liver: A) R6G, B) valsartan, C) 
E217βG 
 
R6G (0. 1 μmol/kg), valsartan (0.5 μmol/kg), and E217βG (0.5 μmol/kg) were each intravenously 
administered to rats (n = 3). Blood and liver samples were collected at 1, 3 and 5 min after 
administration. Closed and open symbols represent the plot of SD rats and EHBRs, respectively. 
Slopes of integration plots represent hepatic uptake clearance. 
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Table II-1. Model-independent pharmacokinetic parameters after the bolus injection of R6G in 
SD rats and EHBRs. 
 
 
 
 
 
* = P < 0.05; ** = P < 0.01; *** = P < 0.001 versus SD rats 
 
R6G (0.5 μmol/kg) was intravenously administered to bile duct-canulated SD rats and EHBRs (n = 3). 
Biliary clearance (CLbile) based on plasma concentration was calculated as the product of total 
clearance and excretion rate. Means ± standard deviations are presented. 
  
 
SD rats EHBRs 
CLtot (ml･min
-1･kg-1) 13.3 ± 2.12 0.833 ± 0.117 *** 
CLbile (ml･min
-1･kg-1) 10.4 ± 1.47 0.425 ± 0.083 *** 
Vdss (ml/kg) 486 ± 97 262 ± 23 * 
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Table II-2. Kinetic parameters of R6G after bolus injection in SD rats and EHBRs 
 
 
 
 
 
 
* = P < 0.05; ** = P < 0.01; *** = P < 0.001 versus SD rats 
 
Time profiles of R6G plasma concentration and R6G cumulative biliary amount in rats (0.5 μmol/kg) 
were fitted to the two-compartment model shown in Figure II-1. Means ± standard deviations are 
presented. 
  SD rats EHBRs 
S1 (l/kg) 0.193 ± 0.036 0.243 ± 0.027 
ke (1/h) 0.854 ± 0.837 0.111 ± 0.083 
k12 (1/h) 7.297 ± 3.068 0.267 ± 0.086 * 
k21 (1/h) 0.745 ± 0.316 0.282 ± 0.352 
kbile (1/h) 0.822 ± 0.064 0.168 ± 0.078 *** 
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Table II-3. Hepatic uptake clearance of Mrp2 substrates in SD rats and EHBRs in an 
integration plot study. 
 
 
 
 
 
 
 
 
* = P < 0.05; ** = P < 0.01; *** = P < 0.001 versus SD rats 
 
R6G (0.1 μmol/kg), valsartan (0.5 μmol/kg), and E217βG (0.5 μmol/kg) were intravenously 
administered to the rats (n = 3) each. Blood and liver samples were collected at 1, 3 and 5 min after 
administration. Uptake clearance was calculated from the slope of an integration plot. Means ± 
standard errors are presented. 
 
  
Compounds 
CLuptake Reduction rate in EHBRs 
SD rats EHBRs compared with SD rats 
 ml･min-1･g liver-1  
R6G 0.394 ± 0.086 0.135 ± 0.031 ** 66% 
valsartan 0.465 ± 0.104 0.024 ± 0.004 *** 95% 
E217βG 0.856 ± 0.055 0.798 ± 0.189 no change 
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Conclusion 
In the chapter I, this study demonstrated that 1) the intestinal glucuronidation of raloxifene 
and biochanin A effectively lower the bioavailability, 2) Ugt1As play a major role in the 
glucuronidation of raloxifene in both liver and intestine, and 3) there is a species difference in 
contribution of intestinal and hepatic glucuronidation of raloxifene to the first-pass effect between rats 
and dogs. These findings suggest that the evaluation of intestinal and hepatic glucuronidation for 
NCEs is important to improve their pharmacokinetic profiles. 
In the chapter II, this study demonstrated that the hepatic uptakes for R6G and valsartan 
were reduced in EHBRs compared to SD rats, but not for E217βG. This mechanism is unclear at 
present. It may be related to the difference in substrate specificity of transporters and/or inhibition of 
hepatic uptake by endogenous substances. It is desirable to consider the possibility of secondary 
effects on the hepatic uptake process for organic anions to explain their enhanced systemic exposure 
in EHBRs. This finding is important for a better prediction of the drug disposition in humans based on 
animal or in vitro uptake experiments. 
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Appendices 
 
 
 
Figure AP-1. Plasma concentration versus time profiles of three compounds after oral 
administration. 
 
Closed symbols ■, systemic plasma concentrations; open symbols □, portal plasma concentrations.  
▲ and ∆, Parents; ■ and □, their glucuronides.  
Gemfibrozil (A), mycophenolic acid (B), and biochanin A (C) were orally administered to SD rats. 
Glucuronides of mycophenolic acid were not detectable. Each symbol represents the mean and the 
error bars indicate the S.D. 
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Figure AP-2. Estimation of Fg from in vitro data by Qgut model. 
 
Fg values of four compound were estimated by Qgut model, defined in eqs. A1 and A2 (Yang, 2007): 
Fg = Qgut / ( Qgut + fu, g･CLint, u)             (A1) 
Qgut = Qvilli･CLperm  / ( Qvilli + CLperm)        (A2) 
Qgut means a hybrid parameter consisting of both Qvilli (villus blood flow) and cellular permeability 
(CLperm). CLperm values were calculated from physiochemical properties (Winiwarter, 1998) and the 
calculated cylindrical surface area of the 60cm segments with radius of 2.2mm, which is enlarged to 
about 600 times for the feature of microvilli (DeSesso, 2001). Qgut was calculated using CLperm and rat 
Qvilli of 14.4 ml･h
−1･kg−1 (Davies, 1993). The fraction unbound in the gut (fu, g) was assumed to be 1, 
and intestinal intrinsic clearance (CLint, u) obtained by microsomal incubation was scaled up to give 
CLint, u per gram of tissue by correcting the values of organ weight and the content of microsomal 
protein (Martignoni, 2006). Predicted Fg values were compared with observed Fa･Fg values. 
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Figure AP-3. Compartmental pharmacokinetic modeling of valsartan and E217βG in rats. 
 
Compartmental pharmacokinetic modeling of valsartan after the bolus injection was performed in A) 
SD rats and B) EHBRs using literature data reported by Yamashiro (2006). Similarly, that of E217βG 
was performed in C) SD rats and D) EHBRs using literature data reported by Morikawa (2000). 
Closed and open symbols represent plasma concentration and cumulative biliary amounts, 
respectively. Solid and dashed lines represent the simulated curves of plasma concentration and 
cumulative biliary amounts, respectively. 
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Figure AP-4. Time-dependent transport of [
14C] R4’G into human MRP2- and MRP3- 
expressing membrane vesicles.  
 
Time-dependent uptakes of [
14C] R4’G into A) human MRP2- and B) human MRP3-expressing 
membrane vesicles in the presence of ATP/AMP were presented and compared with those into control 
membrane vesicles. R4’G is a major metabolite of raloxifene in human. Closed and open symbols 
represent values of human MRP2/3-expressing membrane vesicles and control membrane vesicles, 
respectively. Square and triangular symbols represent values of the reactions with ATP and AMP, 
respectively. 
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Figure AP-5. Plasma concentration and biliary excretion rate versus time profile and liver 
concentration of R6G under steady state in rats. 
 
Raloxifene (0.5 μmol･h−1･body−1) was administered to bile duct-canulated rats (n = 3) by continuous 
intravenous infusion after bolus injection (0.72 μmol/body). Blood and bile samples were collected at 
1, 2, 3, and 4 h after administration, and liver was extracted at the final point. Raloxifene and R6G 
concentrations in plasma, bile, and liver were measured by LC-MS/MS. A) Closed and open symbols 
represent plasma concentration of R6G in SD rats and EHBRs, respectively. B) Closed and open 
symbols represent biliary excretion rate of R6G in SD rats and EHBRs, respectively. C) Closed and 
open bars represent liver concentration of R6G in SD rats and EHBRs, respectively.  
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Figure AP-6. Time-dependent uptake of A) R6G and B) valsartan into rat hepatocytes 
 
The hepatocytes isolated from SD rats and EHBRs were suspended (2×10
6
 cells/ml) in Krebs- 
Henseleit (KH) buffer on ice. After pre-incubating the hepatocyte suspension at 37°C for 2 min, the 
reaction was started by adding the same volume of KH buffer containing A) [
14
C] R6G (final 0.5 µM) 
and B) valsartan (final 5 µM). At the designated time, the uptake was terminated by separating the 
cells from the KH buffer by the centrifugal oil filtration method. As control, the uptake assay was 
additionally conducted on ice (at 4°C). The concentrations of radioactive and non-labeled compound 
in cells were measured by a liquid scintillation counter and LC-MS/MS, respectively. 
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Figure AP-7. Comparison of uptake of three compounds into rat hepatocytes. 
 
The hepatocytes isolated from SD rats and EHBRs were suspended (2×10
6
 cells/ml) in KH buffer on 
ice. After pre-incubating the hepatocyte suspension at 37°C for 2 min, the reaction was started by 
adding the same volume of KH buffer containing [
14
C] R6G (final 0.5 µmol/L), valsartan (final 5 
µmol/L), and [
3
H] E217βG (final 0.1 µmol/L). The uptake was terminated at 0.75, 1, and 2 min, 
respectively by separating the cells from the KH buffer by the centrifugal oil filtration method. As 
control, the uptake assay was additionally conducted on ice (at 4°C). The concentrations of 
radioactive and non-labeled compound in cells were measured by a liquid scintillation counter and 
LC-MS/MS, respectively. 
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Figure AP-8. Influence of plasma components on the uptake of [
14
C] R6G uptake into rat 
hepatocytes. 
 
The hepatocytes isolated from SD rats were suspended (2×10
6
 cells/ml) in KH buffer. KH buffer was 
substituted 50% or 95% by the plasma obtained from SD rats and EHBRs. After pre-incubating these 
hepatocyte suspensions at 37°C for 2 min, the reaction was started by adding the same volume of KH 
buffer and the plasma containing [
14
C] R6G (final 0.5 µmol/L). The uptake was terminated at 1 min 
by the centrifugal oil filtration method. As control, the uptake assay was additionally conducted on ice 
(at 4°C). The concentrations of radioactive were measured by a liquid scintillation counter. 
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Table AP-1. Kinetic parameters of valsartan and E217βG after bolus injection into SD rats and 
EHBRs. 
 
1) Fixed parameters 
 
Kinetic parameters of valsartan and E217βG in SD rats and EHBRs were estimated from the time 
profiles of concentrations in plasma and bile after intravenous administration as reported by 
Yamashiro (2006) and Morikawa (2000). Optimized values and fitting standard deviations (in 
parentheses) are presented. 
Compounds 
 Dose 
SD rats EHBRs References 
[
3
H]E217βG 
180 pmol/kg, i.v. bolus 
S1 (l/kg)    205 (101) 
ke (1/h)   0.0152 (0.0188) 
k12 (1/h)  0.557 (0.431) 
k21 (1/h)  0.112 (0.067) 
kbile (1/h)  0.0470 (0.0081) 
     228 (25) 
   0.0608 (0.0074) 
   0.132 (0.022) 
   0.0462 (0.008) 
   0.00436 (0.00048) 
Morikawa et al. 
(2000) 
[
3
H]valsartan 
1 mg/kg, i.v. bolus 
S1 (l/kg)    80.7 (17.2) 
ke (1/h)   0.00001 (−) 
1)
 
k12 (1/h)  0.380 (0.065) 
k21 (1/h)  0.0168 (0.0028) 
kbile (1/h)  0.0129 (0.0013) 
     65.9 (6.1) 
   0.00001 (−) 1) 
   0.0500 (0.0119) 
   0.0186 (0.052) 
   0.00199 (0.00026) 
Yamashiro et al. 
(2006) 
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Table AP-2. Biliary clearance of raloxifene and R6G under steady state in rats. 
 
 
SD rats EHBRs 
Raloxifene         
CLtot (ml･min
-1･kg-1) 61.5  ±  16.6 374  ±  64.5 
CLbile (μl･min
-1･kg-1) 1.03  ±  0.62 4.20  ±  1.04 
Kpliver 31.5  ±  14.9 101  ±  22.2 
R6G 
    CLbile (ml･min
-1･kg-1) 4.78  ±  1.57 0.283  ±  0.271 
Kpliver  32.1  ±  35.2 7.62  ±  2.60 
 
Raloxifene (0.5 μmol･h−1･body−1) was administered to bile duct-canulated rats (n = 3) by continuous 
intravenous infusion after bolus injection (0.72 μmol/body). Blood and bile samples were collected at 
1, 2, 3, and 4 h after administration, and liver was extracted at the final point. Raloxifene and R6G 
concentrations in plasma, bile, and liver were measured by LC-MS/MS. Biliary clearances of 
raloxifene and R6G under steady state in rats were estimated based on the concentration in the liver. 
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Table AP-3. Classified list of Mrp2 substrates: difference in initial distribution between EHBRs 
and SD rats. 
 
Compounds with initial distribution rate remarkably reduced in EHBRs. 
[
14
C]temocapril (Ishizuka et al., 1997) 
[
3
H]valsartan (Yamashiro et al., 2006) 
[
14
C]S-8921G (Sakamoto et al., 2008) 
TA-0201CA (Fukuda et al., 2010) 
R6G (this study) 
Compounds with initial distribution rate not reduced (or less reduced) in EHBRs. 
cefodizime (Sathirakul et al., 1993) 
DBSP (Sathirakul et al., 1993) 
indocyanine green (Sathirakul et al., 1993) 
HSR-903 (Murata et al., 1998) 
[
14
C]telmisartan (Nishino et al., 2000) 
[
3
H]E 217βG (Morikawa et al., 2000) 
[
14
C]olmesartan (Nakagomi-Hagihara et al., 2006) 
[
11
C]dehydropravastatin (Shingaki et al., 2014) 
 
Pharmacokinetic data of organic anions including plasma and bile concentration in SD rats and 
EHBRs were collected and classified based on the difference in initial distribution between these rats. 
All compounds collected show reduced bile excretion rates in EHBRs compared to those in SD rats 
due to hereditary deficiency of Mrp2, whereas they have different profiles in alteration of initial 
distribution between these rats. A decrease in initial distribution rate in EHBRs is presumably caused 
by reduction of hepatic uptake clearance. They are classified to two types: compounds with initial 
distribution rate remarkably reduced or not (less reduced) in EHBRs. 
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